Literature DB >> 20683042

Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.

E Carreras1, J Y Cahn, C Puozzo, N Kröger, G Sanz, A Buzyn, A Bacigalupo, J P Vernant.   

Abstract

This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coefficient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683042

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.

Authors:  Francine A de Castro; Chiara Piana; Belinda P Simões; Vera L Lanchote; O Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

2.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

Review 3.  Chemotherapy-Related Neurotoxicity.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

Review 4.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

5.  Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan.

Authors:  Maria Sacramento Diaz-Carrasco; Raquel Olmos; Miguel Blanquer; Javier Velasco; Andrés Sánchez-Salinas; José María Moraleda
Journal:  Int J Clin Pharm       Date:  2013-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.